• Patient-Derived Gastric Cancer Assembloids

  2026-09-14

  Shapira-Netanelov and colleagues developed a patient-derived gastric cancer assembloid model that combines matched tumor organoids with stromal cell subpopulations from the same tumor. The system reproduced important tumor–stroma effects on gene expression and drug response, providing a more physiologically relevant platform for biomarker discovery, resistance studies, and personalized treatment research.

• MG-262 in Proteasome and Muscle Aging Research

  2026-09-14

  MG-262 enables reversible, cell-permeable disruption of proteasome chymotryptic activity for studying ubiquitinated-protein accumulation, apoptosis, and cell-cycle control. Its strongest use-case is as a complementary perturbation in muscle proteostasis experiments, where it can be paired with chaperone-mediated autophagy reporters without being mistaken for a CMA-specific inhibitor.

• Anti-M1R/B6R Antibodies and Bispecific Protection

  2026-09-13

  The reference study mapped antibody responses to the orthopoxvirus immunogens M1R and B6R, then used the resulting functional information to develop antibody cocktails and bispecific formats with enhanced antiviral activity. Its strongest translational result was protection against vaccinia virus in mice by a VH-CH1 switch region-inserting bispecific design, although clinical applicability remains untested.

• EZ Cap™ Human PTEN mRNA (ψUTP) Workflow

  2026-09-12

  Use EZ Cap™ Human PTEN mRNA (ψUTP) to restore transient PTEN expression in mechanistic assays, drug-resistance models, and nanoparticle delivery studies. Its Cap 1 structure, poly(A) tail, and pseudouridine modification support translation-focused experiments while helping limit RNA-mediated innate immune activation.

• JZL184 and the Astrocyte–CB1–GLT-1 Axis

  2026-09-11

  JZL184 is more than a selective monoacylglycerol lipase inhibitor: it is a strategic probe for connecting 2-AG metabolism, CB1 signaling, astrocyte glutamate handling, and neuronal injury. This thought-leadership analysis translates recent traumatic brain injury findings into a rigorous framework for experimental design, mechanistic validation, and translational decision-making.

• KR-12: From Membrane Disruption to Translation

  2026-09-11

  KR-12 is more than a compact antimicrobial fragment: its membrane activity, LPS neutralization, biofilm effects, copper binding, and inflammation-modulating potential create a translational research platform. This article connects mechanistic biology with study design and product selection.

• AG-490 (JAK2/EGFR inhibitor): Assay Guide

  2026-09-10

  A scenario-based guide to using AG-490 (JAK2/EGFR inhibitor), SKU A4139, for viability, proliferation, and pathway-inhibition studies. It connects documented target potency, solvent handling, and interpretation limits with recent evidence on JAK2/STAT6 signaling in hepatocellular carcinoma research.

• Nanozyme Hydrogel Breaks the ROS–Ferroptosis Cycle

  2026-09-10

  The reference study develops a ROS-responsive hydrogel containing nucleus pulposus cell membrane-coated black phosphorus@cerium oxide nanozymes to interrupt the linked processes of oxidative stress, ferroptosis, and inflammation in intervertebral disc degeneration. Its central contribution is a dual mechanism that combines durable ROS scavenging with suppression of the IL6/STAT3 pathway through HuR-dependent mRNA stabilization control, offering a mechanistically informed framework for disc repair research.

• A-1210477 MCL-1 Inhibitor Workflow Guide

  2026-09-09

  A-1210477 enables selective interrogation of MCL-1-dependent cancer cell survival and mitochondrial apoptosis in vitro. This guide connects compound handling, dose-response design, apoptosis confirmation, combination testing, and troubleshooting while clearly separating assay evidence from translational limitations.

• Dacomitinib: Designing a Two-Axis Cancer Assay

  2026-09-09

  Dacomitinib (PF-00299804) enables a disciplined two-axis framework linking irreversible pan-HER signaling blockade with mitochondrial ferroptosis research. This article translates METTL17 findings into practical assay decisions without overstating cross-domain evidence.

• CAY10499: Inhibitor of Human Hormone Sensitive Lipase

  2026-09-08

  CAY10499 enables controlled separation of HSL, MGL, and FAAH-dependent lipid hydrolysis from ACLY-driven lipid synthesis in macrophage and tumor-microenvironment models. This practical guide covers enzyme assays, EV-based workflows, dose design, controls, and troubleshooting without treating a lipase inhibitor as a substitute for direct ACLY targeting.

• LLC-PK1-MDR1 Model for BBB Permeability Prediction

  2026-09-08

  The 2025 Drug Delivery study presents a high-throughput Transwell blood-brain barrier model that pairs LLC-PK1-MOCK and LLC-PK1-MDR1 cells with permeability, efflux, recovery, and lysosomal-trapping analyses. Its correlation with unbound brain distribution and successful correction of low-recovery compounds provide a mechanism-aware framework for prioritizing CNS drug candidates.

• α-Amanitin Beyond Inhibition: Assay Logic

  2026-09-07

  α-Amanitin is more than an RNA polymerase II inhibitor: it is a mechanistic probe that links transcriptional shutdown with cellular stress and mitochondrial injury. This article explains how to select readouts, interpret cross-domain evidence, and use A4548 responsibly in advanced research.

• Estradiol for Reliable Cell Assays

  2026-09-07

  Learn how Estradiol SKU A8425 can improve interpretation, dosing consistency, and solvent control in cell viability, proliferation, and cytotoxicity workflows. The guide connects practical assay design with estrogen receptor biology and recent organ-protection evidence.

• Mechanism-Based Aneugenicity Assay: 27-Chemical Study

  2026-09-05

  Bernacki and colleagues developed a tiered flow-cytometric strategy that moves beyond detecting genotoxicity to distinguishing tubulin stabilization, tubulin destabilization, and mitotic kinase inhibition. Using TK6 cells, fluorescent Taxol responses, phospho-histone H3, Ki-67, and machine learning, the study demonstrated a practical proof of concept for mechanism-informed aneugenicity assessment.

8171 records 1/545 page Next 12345 下5页 Last page